KAT2B and chronic obstructive pulmonary disease: Almost two decades ago, the role of HATs (CBP, GCN5, p300, and PCAF) was suggested in COPD pathogenesis, and it is demonstrated that HAT inhibitors targeting these molecules could be used in clinical applications as a therapeutic aspect [96].